Phase 3 ADorable-1 trial results show lebrikizumab-libkz provides skin clearance and itch relief in children with moderate to severe atopic dermatitis.

HealthDay News — Digital media use is consistently associated with risks to child and adolescent mental health and development globally, according to a review published online March 9 in JAMA ...

Findings from the FIND-CKD trial indicate finerenone may provide a new treatment option for slowing renal function loss in CKD patients without diabetes.

Bezuclastinib is an oral, selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation, a primary driver of systemic mastocytosis.

In phase 3 clinical trials, tildrakizumab treatment was associated with significantly higher ACR20 response rates at week 24 compared with placebo.

HealthDay News — Microsoft is rolling out a new artificial intelligence (AI) tool designed to help people manage their health. The feature, called Copilot Health, works inside the company’s Copilot ...

All-cause mortality significantly lower with GLP-1 RA use, with consistent benefit across major cancer types, most GLP-1 RA types.

Medical debt associated with increase in probability of deferred dental care, medical care, mental health care ...

Courts may deny motions for judgment notwithstanding the verdict when a jury reaches a reasonable decision based on evidence of a patient's failure to follow a prescribed treatment plan.

HealthDay News — For children aged 2 to 5 years with atopic dermatitis (AD), roflumilast cream 0.05% has a favorable long-term safety profile and efficacy for up to 56 weeks, according to a study ...

Adults aged 18 to 49 years at increased risk for RSV-associated lower respiratory tract disease are now eligible for the ...

A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.